1. Scrip
  2. >>Business

Jardiance Is The Star Of Boehringer’s Show, But Micardis Drag Spoils The Party

 
• By Jo Shorthouse

Jardiance growth offsets Micardis woes as the German major updates the industry on its H1.

SC1808_efficiency_377196124_1200.jpg
Jardiance growth leads the pack

Jardiance (empagliflozin), Boehringer Ingelheim GMBH’s SGLT-2 inhibitor developed in alliance with Eli Lilly & Co., proved to be the star of BI’s 2018 so far, increasing sales by 68% in the first half of the year, making €664m for the German major.

The family-owned company also highlighted the positive study results for Jardiance in the treatment of type 1 diabetes in addition to insulin therapy as a highlight in its H1 round up. Both trials in the EASE Phase III program, which investigated the use of empagliflozin in combination with insulin therapy in adults with type 1 diabetes, met their primary endpoint

More from Business

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

Gilead Joins Pharma’s US Investment Rush

 
• By Alaric DeArment

The company drew praise from the Trump administration as one of multiple companies announcing multibillion-dollar investments in US manufacturing and R&D.

Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer

 
• By Jessica Merrill

The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).

HAYA Raises $65m To Take First Long Non-Coding RNA Program Into The Clinic

 
• By Mandy Jackson

HTX-001 targeting the long non-coding RNA known as Wisper is being developed for non-obstructive hypertrophic cardiomyopathy. HAYA partnered with Lilly last year in obesity.

More from Scrip

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

HAYA Raises $65m To Take First Long Non-Coding RNA Program Into The Clinic

 
• By Mandy Jackson

HTX-001 targeting the long non-coding RNA known as Wisper is being developed for non-obstructive hypertrophic cardiomyopathy. HAYA partnered with Lilly last year in obesity.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’